Lee. Neutrophil elastase stimulates human airway epithelial cells to produce PGE2 through activation of p44/42 MAPK and upregulation of cyclooxygenase-2. Am J Physiol Lung Cell Mol Physiol 285: L925-L930, 2003. First published June 27, 2003 10.1152/ajplung. 00182.2002The responses of airway epithelium following exposure to neutrophil elastase (NE) were investigated. Human bronchial epithelial cells were explanted on insert surfaces of a modified air-liquid interface culture system to which NE was added to stimulate epithelial cells. PGE2 release significantly increased within 10 min of incubation with NE and peaked 3 h after NE (20 g/ml) stimulation. This action required proteolytic activity as ␣1-antitrypsin blocked NE-induced PGE2 release. The production of PGE2 was also inhibited by indomethacin; a selective cyclooxygenase (COX)-2 inhibitor, celecoxib; and dexamethasone. Moreover, the mRNA expression for COX-2 relative to that for a housekeeping gene was approximately eightfold that of the unstimulated cells. Dexamethasone inhibited COX-2 gene transcription. We further observed that NE-induced PGE2 release involved activation of p44/42, but not p38, MAP kinases. Such p44/42 MAP kinases were rapidly phosphorylated, with the concentration of phosphorylated p44/42 MAP kinases peaking at 10 min after stimulation and declining in culture at 90 min. The specific p44/42 MAP kinase inhibitor UO126 completely blocked p44/42 phosphorylation and, subsequently, PGE2 production. The airway epithelium may play important bronchoprotective and immunomodulatory roles in chronic neutrophilic inflammation.
RATHER THAN FUNCTIONING as a passive barrier, the human airway epithelium can respond to injury, infection, or inflammation by producing various cytokines and mediators to modulate airway inflammation. Certain exogenous or endogenous stimuli can directly affect epithelial cells to increase the generation of IL-8; granulocyte-macrophage colony-stimulating factor; regulated on activation, normal T cell expressed, and presumably secreted; TNF-␣; or PGE 2 (5, 16, 21, 30) . PGE 2 , a metabolite of cyclooxygenase (COX), has been shown to exert a variety of anti-inflammatory and bronchoprotective effects both in vitro and in vivo. PGE 2 may prevent allergen-induced bronchoconstriction (9) , relax airway smooth muscle (17) , inhibit cholinergic neurotransmission (12) , and modulate fibroblast proliferation (20) .
Neutrophil elastase (NE), stored in the azurophilic granules, has been reported to play an important role in stimulating mucus secretion (7) , decreasing ciliary function (3), and increasing epithelial permeability (27) and tissue destruction (15) . NE may contribute to several inflammatory disorders, including emphysema (29) , chronic bronchitis (32) , bronchiectasis (31) , cystic fibrosis (13) , and adult respiratory distress syndrome (18) .
Mitogen-activated protein kinases (MAP kinases), a widely studied family of serine/threonine protein kinases, have been reported to participate in multiple directions of cellular programs (28) . These MAP kinases are activated by dual phosphorylation on tyrosine/threonine residues by distinct MAP kinase kinases. c-Jun NH 2 -terminal kinase and p38 MAP kinase can be activated by a variety of extracellular stimuli and may play critical roles in regulating cytokine production. ERK1 (p44) and -2 (p42) are considered to be involved mostly in cell growth, differentiation, and development.
Airway epithelium is likely to be exposed to high levels of NE in chronic neutrophilic inflammation. This investigation attempts to determine the effects of NE on airway epithelium and its signaling pathways. Human airway epithelial cells (HAEC) were grown on modified air-liquid interface culture inserts. NE was employed to stimulate epithelial cells in both the apical and basal directions. We report that NE activates MAP kinases p44/42 and upregulates COX-2 gene expression, which subsequently enhances PGE 2 production from HAEC. These results demonstrate that human airway epithelium may play an important bronchopro-tective and immunomodulatory roles in chronic neutrophilic inflammation.
MATERIALS AND METHODS
Reagents. RPMI 1640, Medium 199, Leibovitz's L-15 medium, fetal bovine serum (FBS), penicillin, streptomycin, amphotericin B, insulin, recombinant human epidermal growth factor, COX-2 oligonucleotides, and superscript preamplification systems for cDNA synthesis were obtained from GIBCO-BRL Life Technologies (Gaithersburg, MD); type IV collagen, all-trans retinoic acid, transferrin, hydrocortisone, dexamethasone, and indomethacin were from Sigma (St. Louis, MO); NE (16,000 units per mg of protein on the substrate MeO-Suc-AI-AI-Pro-Val-pNA; 1 unit hydrolyzes 1 mol of substrate per min at pH 7.5 and 25°C) from Owensville Elastin Products (St. Louis, MO); cell culture inserts and plates from Becton Dickinson Labware (Lincoln Park, NJ); "high pure" RNA isolation kit from Roche Molecular Biochemicals (Mannheim, Germany); PGE 2 ELISA kit from R&D Systems (Minneapolis, MN); Moloney murine leukemia virus reverse transcriptase, Taq DNA polymerase, and 1,4-diamino-2,3-dicyano-1,4-bis (2-aminophenylthio) butadiene (UO126), a selective p44/42 inhibitor from Promega (Madison, WI).
Modified air-liquid interface culture for HAEC. This cell culture procedure was modified from methods described previously (33, 34) . Human bronchus, obtained from surgical lobectomy for lung cancer, was rinsed several times with Leibovitz's L-15 medium containing penicillin (100 U/ml), streptomycin (100 g/ml), and amphotericin B (0.25 g/ml). The tissue was cut into 1-to 2-mm 2 pieces, and 3-4 pieces of tissue were planted with the epithelium side facing down onto six-well culture inserts (growth area of membrane 4.2 cm 2 , pore size 0.4 m) coated with type IV collagen (50 g/cm 2 ). Two milliliters of medium containing antibiotics/ antimycotic, human epidermoid growth factor (1 ng/ml), insulin (2.5 g/ml), transferrin (2.5 g/ml), hydrocortisone (1 g/ml), 2 mM glutamine, and 0.1% FBS in RPMI 1640 and Medium 199 (vol/vol 1:1) were added to the basal chamber, and 100 l were added to the insert. Culture medium in the basal chamber was changed every 48-72 h, and no medium was added to the insert. The airway epithelial cells were grown on a porous membrane, on which they formed a continuous epithelial sheet with the basal aspect exposed to medium and the apical surface exposed to air.
Cells grown on the inserts were confluent after 7-10 days of incubation. The tissue fragments were then transferred to fresh inserts to obtain new growth of epithelial cells. Cells were then dissociated using 0.02% trypsin-EDTA solution and seeded in 24-well culture inserts (growth area of membrane 0.3 cm 2 , pore size 0.4 m) coated with collagen to determine the extent of mediator release following NE stimulation.
Mediator release. Cells (100 l) were seeded in 24-well culture inserts at a density of 1 ϫ 10 5 cells/ml and grown in culture medium (500 l per basal chamber). The purity of epithelial cells appeared to be Ͼ98%, as determined by morphology and by immunocytochemistry with antibodies against cytokeratin for epithelial cells, vimentin for fibroblasts, and myosin for smooth muscle cells. At confluence, NE was added to either apical or basal compartment at a concentration of 5-20 g/ml. To suppress the effect of mediator release induced by NE, we treated cells with ␣ 1-antitrypsin (200 g/ml), dexamethasone (1-100 M), indomethacin (0.1-1 M), or celecoxib (0.5-10 M suspended in dimethyl sulfoxide). Supernatants were collected at each time point and stored at Ϫ80°C until assayed for mediators. Cell viability was determined by light microscopy and dye exclusion with trypan blue. Levels of PGE 2 were assayed by ELISA according to the manufacturer's instructions.
Analysis of COX-2 mRNA expression. After the removal of supernatants for mediator measurement, total cellular RNA was isolated from cell monolayers using a high pure RNA isolation kit. The RNA (1 g) was reverse transcribed into cDNA using Superscript II RNase H Ϫ reverse transcriptase. An aliquot of cDNA was then subjected to 35 cycles of PCR using a standard procedure denaturing at 94°C for 1 min, annealing at 52°C for COX-2 for 30 s, and elongating at 72°C for 1.2 min. The COX-2-specific primer pair amplified a 769-bp PCR product composed of 5Ј primer GGTCTGGTG CCTGGTCTGATGATG and 3Ј primer CCAGTAGGCAG-GAGAACATATAACA. The constitutively expressed gene adenine phosphoribosyltransferase (APRT) was used as an internal control. The primers for APRT were 5Ј primer GCT-GCGTGCTCATCCGAAAG and 3Ј primer CCTTAAGC-GAGGTCAGCTCC, generating a 246-bp PCR product. The respective amplified products were subjected to electrophoresis in a 2% agarose gel containing ethidium bromide (0.5 g/ml) and visualized under a UV illuminator. The image was photographed, stored, and analyzed by a photodocumentation system with Photo-Capt software (ETS Vilber-Lourmat, Marne LuVallee Cedex, France). Each band was quantified by calculating the ratio of target cDNA signal to the APRT control, and the mRNA expression was presented as a percentage of the APRT signal.
Western blot analysis of MAP kinases. The primary epithelial cells were exposed to NE in the presence or absence of inhibitors for various time intervals. At the end of treatment, cells were lysed on ice in lysis buffer containing 50 mM Tris ⅐ HCl at pH 8.0, 150 mM NaCl, 1% Nonidet P-40, 0.5% deoxycholate, 0.1% SDS, 1 mM phenylmethylsulfonyl fluoride, pepstatin A (1 g/ml), aprotinin (0.2 U/ml), leupeptin (0.5 g/ml), and 1 mM Na 3VO4. The protein concentration was determined by using a bicinchoninic acid protein assay (Pierce Chemicals, Rockford, IL) with bovine serum albumin as the standard. Equal amounts of total cell lysates (15 g) were solubilized in a sample buffer by boiling for 10 min, fractionated on a 14% SDS-polyacrylamide gel, and transferred onto a nitrocellulose membrane. The membrane was washed with 0.1% Tween 20 supplemented with Tris-buffered saline (TBS) and incubated in a blocking buffer (TBS containing 5% nonfat dry milk and 0.1% Tween 20). Antiphospho-p44/42 (Th 202 /Tyr 204 ) antibody or anti-phospho-p38 (Th 180 /Try 182 ) antibody (Cell Signaling Technology, Beverly, MA) in a 1/1,000 dilution was then applied at 4°C overnight with gentle shaking. After being washed with TBS three times, blots were incubated with a 1/2,000 dilution of a horseradish peroxidase-conjugated secondary antibody (Cell Signaling Technology) for 1 h. The protein bands were visualized using enhanced chemiluminescence (Amersham Pharmacia Biotech, Sunnyvale, CA) and autoradiography with Kodak X-ray film.
Statistics. Data were expressed as means Ϯ SE. Statistical analysis for multiple comparisons was performed by ANOVA. Student's t-test (for cytokine assay data) or the paired Student's t-test (for the mRNA expression data) was employed. Differences at P Ͻ 0.05 were considered significant. 2 release. The effect of NE upon the generation of PGE 2 from HAEC is shown in Fig. 1 . In our preliminary experiments, subsequent to the addition of NE (0.1-80 g/ml, either to the luminal or submucosal side of the epithelial layers), most of the stimulated release of PGE 2 appeared to be in the direction of the submucosa (data not shown). No significant increase in PGE 2 production was observed when NE was Ͻ5 g/ml. Cells incubated with NE (40 g/ml) began to detach within 6 h of its addition. An increase in PGE 2 release was observed after NE (20 g/ml) had been added for a period of 10 min (417 Ϯ 49 vs. 164 Ϯ 25 pg/ ml; P Ͻ 0.05, n ϭ 4). The maximal concentration of PGE 2 (1,387 Ϯ 130 vs. 418 Ϯ 34 pg/ml, stimulated vs. control) was detected in the presence of NE (20 g/ml) at 3 h of incubation. Under the light microscope, cell monolayers appeared to be intact following incubation with NE at the concentration Ͻ20 g/ml. The dye exclusion test using trypan blue indicated that cell viability was Ͼ98% at the end of each experiment.
RESULTS

Effects of NE on PGE
Inhibition of NE-induced PGE 2 release. To suppress the NE-induced PGE 2 release, we treated HAEC with dexamethasone (1-100 M), indomethacin (0.1-10 M), or celecoxib (0.1-10 M). NE-induced PGE 2 generation was abolished by coincubation of cells with dexamethasone (10 M), indomethacin (1 M), or celecoxib (1 M) (Fig. 2) . Dexamethasone, indomethacin, or celecoxib alone had no effect on PGE 2 release (data not shown). The induction of PGE 2 release required proteolytic activity. Preincubation of NE (20 g/ml) with ␣ 1 -antitrypsin (200 g/ml) blocked NE's ability to increase PGE 2 release (Fig. 2) .
COX-2 mRNA expression. To determine how PGE 2 synthesis was related to regulation of the amount of COX-2, a reverse transcription-polymerase chain reaction (RT-PCR) was employed. Although PGE 2 release increased 10 min after the addition of NE, a significant induction of COX-2 mRNA expression was detectable at only 1 h (Fig. 3A) . After stimulation of HAEC with NE (20 g/ml) for 3 h, the COX-2 mRNA expression relative to that for the APRT housekeeping gene was approximately eight times that for unstimulated cells (Fig. 3B) . Dexamethasone (10 M) inhibited the gene transcription for COX-2 to a substantial extent (Fig. 4) .
NE-induced p44/42 MAP kinase phosphorylation.
We further investigated whether NE induced PGE 2 release through MAP kinase phosphorylation, a step necessary for MAP kinase activation. This was confirmed by the detection of phosphorylated forms for MAP kinases by Western blot analysis using specific phospho-MAP kinase antibodies. After NE stimulation, p44/42 MAP kinases were rapidly phosphorylated, with the concentration of phosphorylated p44/42 MAP kinases peaking at 10 min and declining at 90 min (Fig. 5A) . For resting cells, p44/42 phosphorylation was detectable, whereas no p38 phosphorylation was observed in either the presence or absence of NE stimulation (Fig. 5B) . To determine the effect of UO126 on p44/42 MAP kinase activation, we examined the phosphorylation status of these enzymes. Coincubation of cells with NE and UO126 resulted in an inhibition of p44/42 MAP kinase phosphorylation in a dose-dependent pattern (Fig. 6) .
Effect of UO126 on NE-induced COX-2 expression and PGE 2 release. We have observed that the NEinduced PGE 2 release from HAEC involved p44/42 MAP kinase activation and that the phosphorylation was abolished by UO126. Pretreatment of cells with UO126 (10 M) caused a substantial suppression of COX-2 mRNA expression (Fig. 7A ) and a complete inhibition of NE-induced PGE 2 production (Fig. 7B) , which confirmed that p44/42 MAP kinase was involved in NE-induced PGE 2 release. UO126 alone did not affect the levels of PGE 2 .
DISCUSSION
Our findings have demonstrated that NE stimulates PGE 2 production through COX-2 upregulation and that the activation of p44/42 MAP kinases is involved. Stimulated, airway epithelium may play an important role in modulating airway inflammation rather than act as a passive barrier. The NE-induced bronchoprotective activities of bronchial epithelium may represent a natural defense mechanism of the airways to regulate inflammatory processes in chronic neutrophilic inflammation.
Within the range of concentrations that could be detected in patients with asthma or cystic fibrosis (27 Ϯ 11 vs. 466 Ϯ 121 g/ml) (6), NE (20 g/ml) significantly increased PGE 2 release into the cell culture supernatants. This increase was abrogated by dexamethasone and nonsteroid anti-inflammatory drugs such as indomethacin and the selective COX-2 inhibitor celecoxib. To identify the upstream enzyme that is responsible for PGE 2 production, we used semiquantitative RT-PCR to examine expression of COX-2. COX-1 is constitutively expressed, whereas COX-2 is highly inducible by a number of cytokines and is associated with inflammatory processes (21, 23) . We observed that COX-1 expression appeared to be constant at a very low level and not inducible (data not shown). By contrast, COX-2 expression following NE stimulation rose in a time-and dose-dependent pattern, which was mimicked by subsequent PGE 2 release. Recent evidence has suggested that COX-2-dependent PGE 2 release may play a role in the resolution of inflammation (10) . The transcription of COX-2 gene was completely blocked by dexamethasone, and this blockage resulted in substantial reduction of PGE 2 production. The mechanism and therapeutic effects of steroids for treatment of inflammatory airway disorders (such as asthma) appear to be well understood. However, the beneficial or deleterious consequences of dexamethasone resulting in the suppression of COX-2 expression and PGE 2 production remain to be elucidated.
At a concentration of Ͼ40 g/ml, NE elicited cell detachment. The NE-induced shedding of airway epi- thelium is thought to be due to proteolytic cleavage of the extracellular matrix. This may result in goblet cell metaplasia and an impaired mucociliary clearance, which have been observed in several inflammatory lung diseases (11) . Proteolytic activity was required for NE to induce PGE 2 production as this activity was abolished by coincubation of cells with ␣ 1 -antitrypsin. The culture medium has some growth factors as described previously. However, PGE 2 levels in the control groups did not change significantly within 24 h of incubation. The only difference between control and treatment groups was the presence of NE. It is unlikely that some protein, released following protease reaction, stimulates PGE 2 production in an autocrine manner within a few minutes. It is possible that NE stimulates PGE 2 production through activation of proteaseactivated receptors (PAR), especially PAR-2, which is specific for serine proteases such as NE. A blocking antibody for PAR-2 will need to be developed to clarify whether NE stimulates epithelial cells through the activation of PAR-2 or via other mechanisms that subsequently enhance phosphorylation of MAP kinases and COX-2 gene transcription.
It has been reported that IL-1␤ can induce PGE 2 production in human bronchial epithelial cells (22) and gastric epithelial cells (8) through the activation of p38 and p44/42 MAP kinases and upregulation of COX-2. Proinflammatory mediators, such as TNF-␣, IL-1␣, and platelet-activating factor, can induce IL-8 expression within bronchial epithelial cells via a p38 MAP kinase-dependent pathway (19) . To identify the mechanism of NEinduced PGE 2 production, we have investigated the signal pathways including p38 and p44/42 MAP kinases. Our results have shown that p44/42, but not p38, MAP kinases were rapidly phosphorylated following NE stimulation, and this phosphorylation was inhibited by UO126. UO126, specific inhibitor of p44/42 MAP kinases, suppressed NE-induced COX-2 mRNA expression and PGE 2 release. However, p38 phosphorylation was not observed even in the presence of NE stimulation.
Rather than using bronchial epithelium-derived cell lines, cells employed in this study were primary epithelial cells explanted from human bronchus. The characteristics and responses are believed to be more authentic than those of cell lines. Our preliminary experiments have indicated that most of the stimulated release of PGE 2 was in the direction of the submucosa (data not shown). This observation would appear to be consistent with a previous study suggesting that Ͼ95% of the PGE 2 produced by dog trachea epithelium is released in the submucosal direction following eosinophil major basic protein stimulation (14) . This provides the opportunity for epithelium-released PGE 2 to influence the underlying tissues, such as nerves, smooth muscle, and inflammatory cells. PGE 2 possesses potentially important bronchoprotective and anti-inflammatory properties in vitro and may elicit bronchodilation when introduced into asthmatic airways in vivo (24) . PGE 2, the so-called "epithelium-derived relaxing factor," may play an important role in regulating airway tone. Airway epithelium removal prevented PGE 2 production and thus increased the contractile response of smooth muscles evoked by acetylcholine, histamine, and PGF 2␣ (1) . Furthermore, PGE 2 is able to inhibit the release of mediators from lung mast cells (26) and inhibit eosinophil chemotaxis and cytokine-stimulated eosinophil survival as well as IL-2 production by T lymphocytes and IL-4-induced IgE production by B lymphocytes (2, 4, 25) .
In summary, bronchial epithelium is an effector and regulator of airway inflammation and smooth muscle tone. The ways to enhance bronchoprotection by bronchial epithelium may be of great value in the future treatments of chronic inflammatory disorders of the airways.
